Dr. Xia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3300 Gallows Rd
Falls Church, VA 22042Phone+1 703-776-4001Fax+1 703-776-7113
Education & Training
University of Texas Medical Branch HospitalsResidency, Pathology-Anatomic and Clinical, 2012 - 2016- University of Texas Medical Branch HospitalsResidency, Pathology-Anatomic and Clinical, 2011 - 2015
University of Texas Southwestern Medical SchoolClass of 2011
Certifications & Licensure
VA State Medical License 2016 - 2026
TX State Medical License 2016 - 2025
PA State Medical License 2014 - 2016- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
Publications & Presentations
PubMed
- 15 citationsDNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma.Iván González, Bella Goyal, Michelle Xia, Reetesh K. Pai, Changqing Ma
Human Pathology. 2019-03-01 - 6 citationsExpression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma.Michelle Xia, Michael J. Overman, Asif Rashid, Deyali Chatterjee, Hua Wang
Human Pathology. 2015-09-01 - 1 citationsBoerhaave syndrome resulting from homicidal blunt trauma.Michelle Xia, Stephen Pustilnik
The American Journal of Forensic Medicine and Pathology. 2014-09-01
Journal Articles
- Original Contribution DNA Mismatch Repair Deficiency but Not ARID1A Loss Is Associated with Prognosis in Small Intestinal Adenocarcinoma☆☆☆Michelle D Xia, Bella Goyal, ScienceDirect
Press Mentions
Akeso Reported 2022 Annual ResultsMarch 16th, 2023- Akeso Announced 2023 Interim Results: First Profit, Growing Sales of PD-1/CTLA-4 Bispecific Antibody and Priority Review of PD-1/VEGFAugust 31st, 2023
- Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic SyndromesSeptember 29th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
